Summary
Updated Aug 30, 2026
Dipal Doshi is CEO, Director of Entrada Therapeutics, Inc. (TRDA). 3 SEC Form 4 filings on record going back to 2025, most recently on 3 March 2026.
Recent Transactions
5Every recent SEC Form 4 transaction Dipal Doshi has reported, most recent first.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Dipal Doshi files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Kush Parmar - $3.65M of TRDA open-market activity in the last 12 months
- 5AM Ventures V, L.P. - $3.00M of TRDA open-market activity in the last 12 months
- BAKER BROS. ADVISORS LP - $1.61M of TRDA open-market activity in the last 12 months
- MPM BioVentures 2014, L.P. - $462K of TRDA open-market activity in the last 12 months
- MPM BIOVENTURES 2018, L.P. - $462K of TRDA open-market activity in the last 12 months
- Kory James Wentworth - $434K of TRDA open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Dipal Doshi?
Dipal Doshi is a corporate insider, tracked as CEO, Director of Entrada Therapeutics, Inc. (TRDA). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Dipal Doshi last file a Form 4?
The most recent primary Form 4 on record is dated 3 March 2026, one of 3 filings going back to 2025.
Where can I see all of Dipal Doshi's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Dipal Doshi and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
